C₂N Diagnostics reports positive data for new Alzheimer’s blood test
The combination of the p-tau217 ratio and Aβ42/40 ratio enables the identification of Alzheimer’s brain pathology patients.

The combination of the p-tau217 ratio and Aβ42/40 ratio enables the identification of Alzheimer’s brain pathology patients.
Natus shareholders received $33.50 in cash for each share of company common stock.
Brain-computer interfaces, IoT and AI to fuel the advancement of assistive technology devices for ALS patients.
ByFirst Relief is placed behind the ear and provides continuous pulses of low-level electrical current.
p-tau MAA is expected to provide researchers with an additional tool for Alzheimer’s and brain health studies.
The AlzoSure Predict test has already received Breakthrough Device designation from the US FDA.
The FDA-cleared ReGrasp Bionic Glove can be used to improve hand function after stroke or injury.
The companies expect to receive a minimum additional $10m in equity from Lakeshore's trust account or a PIPE.
Thank you for subscribing to Medical Device Network